Wednesday 13:00-13:45, Hall 8

Despite considerable advances in the medical management of ulcerative colitis (UC) there remain several areas of unmet need for UK patients and physicians. These include a lack of response and/or intolerance to current therapies, achieving a rapid onset of clinical effect, maintaining long term steroid free remission, and incorporating individual patient goals into disease management within the NHS.

Session Overview:

  • JAK1 preferential inhibition: what does it mean?
  • Clinical relevance of filgotinib in moderate to severe UC
  • Managing moderate to severe UC patients with filgotinib

Speakers:

Professor Miles Parkes, Consultant Gastroenterologist, Addenbrookes NHS Trust Hospital, Cambridge

Dr Alissa Walsh DPhil FRACP, Consultant Gastroenterologist, Oxford University Hospitals NHS Trust, Oxford

Lisa Younge, Nurse Consultant – Inflammatory Bowel Disease, London North West University Hospital NHS Trust

UK-UC-FIL-202204-00008

May 2022